An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Pediatric Hypertension, High Blood Pressure, Hypertension, Pediatric, Primary Hypertension, Secondary Hypertension
Eligibility Criteria
Inclusion Criteria:
The subject has hypertension (primary or secondary) defined as clinic Seated Diastolic BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by age, gender, height) if chronic renal disease, diabetes, heart failure or hypertensive target organ damage is present
- If currently treated: The subject has a documented historical diagnosis of hypertension AND a post-washout clinic Seated Diastolic BP meeting the above criteria on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)
- If currently untreated: The subject has elevated Seated Diastolic BP meeting the above criteria on 3 separate occasions before Randomization, including on Day -1 (or Day 1 for subjects not participating in Ambulatory Blood Pressure Monitoring)
- The subject is male or female and aged 6 to <18 years at Baseline and weighs at least 25 kg
- The subject agrees to continue their previously implemented nonpharmacological life style modifications if begun prior to Screening. Note: For subjects participating in a weight loss program, the weight maintenance
Exclusion Criteria:
- The subject has a clinic Seated Diastolic BP greater than 15 mm Hg and/or Seated Diastolic BP greater than 10 mm Hg above the 99th percentile for age, gender, and height as confirmed by the average (arithmetic mean) of 3 serial clinic seated BP measurements at Screening/Visit 1
- The subject has a diagnosis of malignant or accelerated hypertension
- The subject is currently treated with more than 2 antihypertensive agents
- The subject or parent/legal guardian is not willing for the subject's previous antihypertensive medications to be stopped
- The subject has participated in the intensive, active weight-loss phase of a weight-loss program within 30 days prior to Screening/Visit 1
- The subject has any of the following: severe renal impairment (eGFR <30 mL/min/1.73 m2 by the Schwartz formula); is currently undergoing dialysis treatment; renovascular disease affecting both kidneys or a solitary kidney; severe nephrotic syndrome not in remission; or serum albumin <2.5 g/dL
- The subject has a history or clinical manifestations of severe cardiovascular, hepato-biliary, gastrointestinal, endocrine-metabolic (e.g., hyperthyroidism, Cushing's syndrome), hematologic, immunologic, genito-urinary, or psychiatric disease, cancer, and/or any conditions that would interfere with the health status of the subject through study participation, or would jeopardize study integrity in the opinion of the investigator
- The subject is suffering from uncorrected coarctation of the aorta, or hemodynamically significant left ventricular outflow tract obstruction due to eg, aortic valvular disease, or is likely to undergo a procedure known to affect blood pressure (eg, repair of arterial anomalies) during the course of the study
- The subject is poorly controlled diabetic defined as having a glycosylated hemoglobin value >8.5% at Screening/Visit 1
- The subject has hyperkalemia as defined by the central laboratory's normal reference range or any pertinent electrolyte disorders at Screening/Visit
Sites / Locations
- Advanced Research Center, INC
- Direct Helpers Research Center
- JDH Medical Group LLC
- University of Miami/Jackson Memorial Hospital
- Medical Research Center of Miami II, Inc.
- Pioneer Clinical Research
- Georgia Clinical Research
- Zoe Center for Pediatrics
- University of Louisville
- David M. Headley, MD PA
- Mount Sinai PRIME
- Medical University of South Carolina (MUSC)
- Memphis and Shelby County Pediatric Group
- Southeast Texas Clinical Research Center
- Texas Children's Heart Center
- Ericksen Research & Development, LLC
- Mid-Columbia Research
- Hospital Italiano
- Hospital de Niños
- Clinica de Nefrologia, Urologia y Enf. Cardiovasculares S A
- Clínica Nefrokids Ltda
- Hospital São Lucas da PUCRS
- Instituto de Cardiologia do Rio Grande do Sul
- Fundação José Luiz Egydio Setúbal
- Hospital Samaritano
- Eurolatino Pesquisas Médicas Ltda.
- SHATPPD-Ruse EOOD
- Fundacion Oftalmologica de Santander - FOSCAL
- Fundacion Valle del Lili
- Fundacion Hospitalaria San Vicente de Paul
- Hospital Pablo Tobón Uribe
- Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"
- Principal SMO Kft.
- Svabhegy Plusz Gyermekegeszsegugyi Kozpont
- Szent Lukacs Korhaz Dombovar
- Prehospital Med Kft.
- Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Kozp.
- Ospedale Pediatrico Giovanni XXIII
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
- A.R.N.A.S. Ospedale Civico e Benfratelli, G. Cristina e M.Ascoli
- Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
- Hospital General de Mexico
- Accelerium S. de R.L. de C.V.
- Centro de Investigacion Clinica Chapultepec S.A. de C.V.
- SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa
- Uniwersytecki Szpital Dziecięcy w Krakowie
- NZOZ TRI-medica
- Praktyka Lekarzy Rodzinnych R.Jadach, M.Domanski NZOZ
- LCS Clinical Research Unit
- Soweto Clinical Trial Centre
- Netcare St. Anne's Hospital
- Groote Schuur Hospital E13 Renal Unit
- Clinical Projects Research SA (PTY) LTD
- CRISMO Bertha Gxowa Research Centre
- Cukurova University Medical Faculty
- Gazi University Medical Faculty
- Istanbul University Istanbul Medical Faculty
- Dokuz Eylul University Medicine Faculty
- Erciyes University Medical Faculty
- Celal Bayar University Medical Faculty
- CMI Chernivtsi City Children Clinical Hospital
- Regional Children CH Cardiology Department Kharkiv NMU
- SI National Research Center of Radiation Medicine of NAMSU
- USPC of ES EO&T Transplantation of MHU
- HSEI of Ukraine UMSA
- SSU Division MU Ch of pediatrics
- Vynnitsa Regional Children CH pediatric department № 1 M.I. Pyrogov NMU
- CI Zaporizhzhia City Multibranch Children Hospital #5
- CI Zaporizhzhia Regional Clinical Children Hospital of ZRC
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Experimental
Active Comparator
Active Comparator
Placebo Comparator
Experimental
Other
Active Comparator
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Double-blind: Azilsartan Medoxomil - Low dose
Double blind phase: Losartan
WITHDRAWAL Phase: Azilsartan medoxomil LOW-dose
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil LOW DOSE
Open Label Phase: Azilsartan Medoxomil
Open Label Phase: "Other"
Withdrawal Phase: Losartan 50 mg
Withdrawal Phase: PLACEBO to Losartan
Double-blind: Azilsartan Medoxomil - Medium dose
Double-blind: Azilsartan Medoxomil - High dose
WITHDRAWAL Azilsartan Medoxomil - Medium dose
WITHDRAWAL Azilsartan Medoxomil - High dose
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil MEDIUM DOSE
WITHDRAWAL Phase: PLACEBO to match azilsartan medoxomil HIGH DOSE
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil Low-dose (AZM-L), 10 mg once daily.
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Starting at Losartan 25/50 and force titrated to 50/100 mg daily at Week 2.
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil low dose) that was taken in Double blind OR to be switched to placebo.
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil LOW dose) in Double blind then randomized (1:1) to placebo for withdrawal phase
Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
If add-on therapy is needed, a calcium channel blocker, such as amlodipine; a diuretic, such as hydrochlorothiazide; or a beta-blocker such as metoprolol will be determined per the investigator's clinical judgment.
Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
6-week, double-blind (DB), randomized, treatment phase (DB Phase), Azilsartan medoxomil Medium-dose (AZM-M), 20 mg once daily at Week 2.
6-week, double-blind (DB), randomized, treatment phase (DB Phase): Azilsartan medoxomil High-dose (AZM-H), 40 mg AZM-M
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil MEDIUM dose) that was taken in Double blind OR to be switched to placebo.
Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment ( Azilsartan medoxomil HIGH dose) that was taken in Double blind OR to be switched to placebo.
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil MEDIUM dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase
PLACEBO Arm in the Withdrawal Phase for subjects who were on Azilsartan medoxomil HIGH dose) in Double blind then randomized (1:1) to matching placebofor withdrawal phase